A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.
CEO Brian Niccol says employees' questions about share prices reflect pride and care, as the coffee giant navigates workplace reforms and ongoing labor disputes.
A social media poll by billionaire Mark Cuban reveals a near-even split on which part of U.S. health insurance is more financially painful—premiums or deductibles. The results, and the outpouring of personal stories in the replies, underscore a system many describe as forcing impossible choices amid relentlessly rising costs.
Elon Musk is reportedly in discussions to merge his aerospace giant SpaceX with his artificial intelligence venture xAI, aiming to create an integrated powerhouse for deploying AI data centers in orbit, powered by space solar energy.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
In a significant policy shift, Chinese authorities have reportedly cleared the AI startup DeepSeek to purchase Nvidia's advanced H200 processors, potentially easing a major hardware bottleneck for its competitive large language model.
While retirement planning often focuses on savings, a critical financial metric—net worth—reveals a more precarious reality for many households. We examine the causes and consequences of negative net worth, offering actionable steps to build a stronger financial foundation.
Despite lagging the broader market over the past year, Ingersoll Rand shows signs of a strategic pivot. Wall Street sees modest upside potential as the industrial giant navigates headwinds and pursues growth through acquisition.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Amidst economic crosscurrents, a closer look at Ideal Power, NetSol Technologies, and Sono-Tek reveals companies executing distinct strategies to navigate growth and profitability challenges in the high-risk, high-reward penny stock arena.
A couple earning $380,000 annually faces a classic high-cost dilemma: Should they stretch for a $1.8 million dream home now or wait? With a hefty down payment saved but significant student debt, their debate highlights the tension between future earnings potential and present financial anxiety in today's premium housing markets.
